يعرض 1 - 20 نتائج من 282 نتيجة بحث عن '"Y. -J. Park"', وقت الاستعلام: 0.79s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
  3. 3
    Academic Journal

    المساهمون: M.S. Brose: Медицинская школа Пенсильванского университета получила грант на проведение этого исследования, автор получал гонорары за консультации от Eisai, Bayer, Lilly, Loxo и Blueprint Medicines. Yu. Panaseykin: конфликт интересов отсутствует. B. Konda: финансирование исследований (все финансирование для учреждения): Eisai, Merck, Bristol Myers Squibb, Xencor и Eli Lilly & Co. C. de la Fouchardiere: гонорары – Eisai, Roche, Servier, Amgen, Bayer, Pierre Fabre Oncologie и Bristol Myers Squibb, нефинансовая поддержка – Roche, Servier, Amgen, Bayer, Pierre Fabre Oncologie и Bristol Myers Squibb. B.G.M. Hughes: член консультационного совета в Eisai, MSD, Bristol Myers Squibb, Roche, AZ, Pfizer, Boehringer Ingelheim и Takeda. A.G. Gianoukakis: участник медицинского консультационного совета в Eisai и Blueprint. Y.J. Park: конфликт интересов отсутствует. I. Romanov: гонорары – Eisai, Bristol Myers Squibb и Merck Serono. M.K. Krzyzanowska: финансирование исследований (учреждение) – Eisai, Exelixis, Ipsen, гонорары за консультации – Eisai, Bayer, and Lilly. S. Leboulleux: финансирование исследований (учреждение) от Novartis и Sanofi Genzyme, член консультационного совета Eisai, Bayer и Lilly. T.A. Binder: бывший сотрудник (и нынешний консультант) Eisai Inc. C. Dutcus: сотрудник Eisai Inc. R. Xie: сотрудник Eisai Inc. M.H. Taylor: консультант/член консультационного совета (выплачивается вознаграждение) – Bristol Myers Squibb, Eisai Inc., Novartis, Bayer, Sanofi/ Genzyme, Array Biopharma, LOXO Oncology, Blueprint Medicines и Arqule, бюро спикеров (выплачивается гонорар): Bristol Myers Squibb и Eisai Inc., финансирование исследований (все финансирование для учреждения) – Bristol Myers Squibb, Merck Sharp & Dohme Corp, Pharmacyclics, AstraZeneca, Eisai, Incyte, EMD Serono, Novartis, Seattle Genetics, AbbVie, Genentech, Eli Lilly, Roche, Acerta Pharma, Genzyme Corporation и Pfizer.

    المصدر: Head and Neck Tumors (HNT); Том 12, № 1 (2022); 86-98 ; Опухоли головы и шеи; Том 12, № 1 (2022); 86-98 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2022-12-1

    وصف الملف: application/pdf

    Relation: https://ogsh.abvpress.ru/jour/article/view/740/518; Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.; Cabanillas M. E., Habra M. A. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev 2016;42:47–55.; Eustatia-Rutten C. F., Corssmit E. P., Biermasz N. R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9.; Araque K. A., Gubbi S., Klubo-Gwiezdzinska J. Updates on the management of thyroid cancer. Horm Metab Res 2020;52 (8):562–77.; Fleeman N., Houten R., Chaplin M. et al. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer 2019;19(1):1209.; Busaidy N. L., Cabanillas M. E. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012;2012:618985.; Brose M. S., Nutting C. M., Jarzab B. et al. DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, doubleblind, Phase 3 trial. Lancet 2014;384(9940):319–28.; Matsui J., Funahashi Y., Uenaka T. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17):5459–65.; Matsui J., Yamamoto Y., Funahashi Y. et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122(3):664–71.; Tohyama O., Matsui J., Kodama K. et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014;2014:638747.; Yamamoto Y., Matsui J., Matsushima T. et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR / FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014;6:18.; Schlumberger M., Tahara M., Wirth L. J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30.; Lenvima (lenvatinib) [prescribing information]. Eisai Inc;2020.; Locati L. D., Piovesan A., Durante C. et al. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodinerefractory differentiated thyroid cancer patients in Italy. Eur J Cancer 2019;118:35–40.; Kim S. Y., Kim S. M., Chang H. et al. Safety of tyrosine kinase inhibitors in patients with differentiated thyroid cancer: real-world use of lenvatinib and sorafenib in Korea. Front Endocrinol 2019;10:384.; Hayato S., Shumaker R., Ferry J. et al. Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer. Cancer Chemother Pharmacol 2018;82(6):971–8.; Robinson B., Schlumberger M., Wirth L. J. et al. Characterization of tumor size changes over time from the Phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab 2016;101(11):4103–9.; NCCN Thyroid Carcinoma Panel. Thyroid carcinoma. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Version 1. 2021. Accessed June 2, 2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.; Filetti S., Durante C., Hartl D. et al. ESMO Guidelines Committee. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(12):1856–83.; Hao Z., Wang P. Lenvatinib in management of solid tumors. Oncologist 2020;25(2):e302–10.; Kudo M., Finn R. S., Qin S. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet 2018;391(10126):1163–73.; Bullock J. M., Rahman A., Liu Q. Lessons learned: dose selection of small moleculetargeted oncology drugs. Clin Cancer Res 2016;22(11):2630–8.; https://ogsh.abvpress.ru/jour/article/view/740

  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
  8. 8

    المساهمون: University of Washington [Seattle], Howard Hughes Medical Institute [Boston] (HHMI), Howard Hughes Medical Institute (HHMI)-Harvard Medical School [Boston] (HMS), Hong Kong University of Science and Technology (HKUST), Centre de Biologie Structurale [Montpellier] (CBS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Fred Hutchinson Cancer Research Center [Seattle] (FHCRC), Nord, Ashley

    المصدر: Science
    Science, 2022, 376 (6591), pp.383-390. ⟨10.1126/science.abm1183⟩

    وصف الملف: application/pdf

  9. 9
  10. 10
  11. 11
    Academic Journal
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
    Academic Journal

    المصدر: Physical Review Special Topics. Accelerators and Beams, Vol 13, Iss 4, p 042801 (2010)

  17. 17
  18. 18
  19. 19
  20. 20
    Academic Journal